Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedTrust Online and Avantra Biosciences have entered into a partnership to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' revolutionary QPDx multiplex immunoassay system.
Subscribe to our email newsletter
The two companies will provide over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers.
Avantra had announced the commercialisation of the new Q400 Biomarker Workstation and AngioGenQx BioChip immunoassay, which provide quantitative protein biomarker results for 10 analytes in less than an hour, requiring only five minutes for sample preparation.
While Avantra identifies biomarkers of interest for its QPDx system, MedTrust will use its Knowledge Medicine platform to engage oncologists in online discussions to validate the role of different panels in diagnosis, prognosis, and treatment efficacy in cancer care.
The first of several multiplex assays to be evaluated include an upcoming panel developed in the recently announced partnership between Avantra and TGen Drug Development.
Avantra is also planning to develop additional panels that may target ovarian, pancreatic, lung, prostate, breast, and colorectal cancers.
MedTrust Online brings together experts in oncology, information technology, computational biology, pharmaceutical drug development, and personalized medicine to capture, organize, analyze, integrate and present medical facts from a vast array of sources.